Professor: If LymPro does what we all think it will do in 2015, AMBS won't run out of money. That's why everyone is on pins and needles about all of Lympro's delays. If management can deliver LymPro and successfully launch it in December with strong data, a marketing blitz, and several clinical trial work orders....we'll all be fine.